Literature DB >> 14551067

The patient's perspective on medicines in mental illness.

Mike Shooter.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551067      PMCID: PMC214008          DOI: 10.1136/bmj.327.7419.824

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  8 in total

Review 1.  Antidepressants and suicide: risk-benefit conundrums.

Authors:  David Healy; Chris Whitaker
Journal:  J Psychiatry Neurosci       Date:  2003-09       Impact factor: 6.186

Review 2.  Patient adherence in the treatment of depression.

Authors:  S Pampallona; P Bollini; G Tibaldi; B Kupelnick; C Munizza
Journal:  Br J Psychiatry       Date:  2002-02       Impact factor: 9.319

3.  Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events.

Authors:  K Demyttenaere; P Enzlin; W Dewé; B Boulanger; J De Bie; W De Troyer; P Mesters
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

Review 4.  Poverty and common mental disorders in developing countries.

Authors:  Vikram Patel; Arthur Kleinman
Journal:  Bull World Health Organ       Date:  2003-10-14       Impact factor: 9.408

5.  Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder.

Authors:  Virginija Novak-Grubic; Rok Tavcar
Journal:  Eur Psychiatry       Date:  2002-05       Impact factor: 5.361

Review 6.  Efficacy of newer generation antipsychotics in the treatment of schizophrenia.

Authors:  R Tandon; M D Jibson
Journal:  Psychoneuroendocrinology       Date:  2003-01       Impact factor: 4.905

Review 7.  From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication.

Authors:  R Gray; T Wykes; K Gournay
Journal:  J Psychiatr Ment Health Nurs       Date:  2002-06       Impact factor: 2.952

8.  Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.

Authors:  W Löffler; R Kilian; M Toumi; M C Angermeyer
Journal:  Pharmacopsychiatry       Date:  2003-05       Impact factor: 5.788

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.